MYC and cancer: As KRASG12V/MYC cancer cells respond to GNE/BMS combination treatment and allow comparison with their non-cancerous progenitor cells, follow-up experiments were conducted using this cell model for ovarian carcinoma and standard concentrations of GNE (7.5 μM) and BMS (6 μM).